---
title: Surgical Mesh in Radical Cystectomy to Prevent Parastomal Hernias
nct_id: NCT06032910
overall_status: UNKNOWN
phase: NA
sponsor: Charles University, Czech Republic
study_type: INTERVENTIONAL
primary_condition: Bladder Cancer
countries: Czechia
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT06032910.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT06032910"
ct_last_update_post_date: 2024-02-28
last_seen_at: "2026-05-12T06:07:21.985Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Surgical Mesh in Radical Cystectomy to Prevent Parastomal Hernias

**Official Title:** The Use of Surgical Mesh in Open Radical Cystectomy With Ileal Conduit Urinary Diversion to Prevent Parastomal Hernias

**NCT ID:** [NCT06032910](https://clinicaltrials.gov/study/NCT06032910)

## Key Facts

- **Status:** UNKNOWN
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 25
- **Lead Sponsor:** Charles University, Czech Republic
- **Conditions:** Bladder Cancer, Hernia, Ileal Conduit
- **Start Date:** 2023-01-01
- **Completion Date:** 2024-12-31
- **CT.gov Last Update:** 2024-02-28

## Brief Summary

Radical cystectomy with ileal conduit urinary diversion serves as a foundational curative treatment strategy for selected patients afflicted with urothelial carcinoma of the bladder. Parastomal hernia after this procedure is an underestimated and undertreated clinical entity, which heavily impairs patients' quality of life due to symptoms of pain, leakage, application or skin problems. There is little evidence about prophylactic mesh placement for parastomal hernia prevention. In this study we examine the use of meshes during radical cystectomy and compare them with a control group.

## Detailed Description

Radical cystectomy with ileal conduit diversion is a procedure possible with complications. A primary stoma-related complication is the parastomal hernia (PH), which presents significant challenges to both the medical community and the patient. PH is classically defined as the protrusion of abdominal contents via the abdominal wall, especially in the direct vicinity of a stoma, whether it be a colostomy, ileostomy, or ileal conduit stoma. The incidence of PH post ileal conduit urinary diversion is especially concerning, with reports estimating its occurrence at around 17%. This data only emphasizes the need to reevaluate and optimize surgical treatments for PH, particularly as, in many cases, management strategies are extrapolated from experiences with colostomies or ileostomies. Notably, PHs are often described after these procedures rather than RC with ileal conduit urinary diversion. Further complicating the issue is the fact that estimates suggest around 30% of patients develop a PH within 12 months post any type of stoma site surgery. For those undergoing ileal conduit urinary diversion specifically, recurrence rates following PH repair can be alarmingly high, with figures as steep as 69% within a year.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* muscle-invasive or high-risk non-muscle-invasive bladder cancer patients

Exclusion Criteria:

* different than surgical therapy
```

## Arms

- **Study group** (EXPERIMENTAL) — Patients who receive prophylactic mesh during the surgery.

## Interventions

- **Surgical mesh** (DEVICE) — Prophylactic synthetic non-absorbable keyhole mesh placement upon construction of ileal conduit.

## Primary Outcomes

- **Parastomal hernia** _(time frame: 12 months)_ — Incidence after surgery

## Locations (1)

- University Hospital Hradec Kralove, Hradec Králové, Czechia — _RECRUITING_

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.university hospital hradec kralove|hradec králové||czechia` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT06032910.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT06032910*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*